BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2727008
Number of visits today
883
Number of downloads
1998389
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Gao Z, Zhong X, Tan YX, Liu D. Apelin‑13 alleviates diabetic nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis. Int J Mol Med 2021;48:175. [PMID: 34278446 DOI: 10.3892/ijmm.2021.5008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 İçen G, Dağlıoğlu G, Evran M. Evaluation of Apelin-13 levels in patients with diabetic nephropathy. Int Urol Nephrol 2023;55:345-53. [PMID: 35925488 DOI: 10.1007/s11255-022-03323-0] [Reference Citation Analysis]
2 Huang W, Chen YY, Li ZQ, He FF, Zhang C. Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. Int J Mol Sci 2022;23:10882. [PMID: 36142794 DOI: 10.3390/ijms231810882] [Reference Citation Analysis]
3 Li C, Cheng H, Adhikari BK, Wang S, Yang N, Liu W, Sun J, Wang Y. The Role of Apelin–APJ System in Diabetes and Obesity. Front Endocrinol 2022;13:820002. [DOI: 10.3389/fendo.2022.820002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Li S, Wang D, Zhang M, Zhang C, Piao F. Taurine Ameliorates Apoptosis via AKT Pathway in the Kidney of Diabetic Rats. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-030-93337-1_22] [Reference Citation Analysis]
5 de Oliveira AA, Vergara A, Wang X, Vederas JC, Oudit GY. Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists. Peptides 2021;147:170697. [PMID: 34801627 DOI: 10.1016/j.peptides.2021.170697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345